We would like to thank this company for presenting at our 5th Annual Small Cap Equity Conference held May 6th, 2008 at the Le Parker Meridien New York City. If you missed the event, you can still hear the presentations via our streaming audio archive.  Click here Listen!

Updated Research Report (November 29, 2007)

Results of the studies were presented at the LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine Department of Pharmacology, who stated that NYU studies showed that the combination of cycled high pressure (PCT) with the ProteoSolve-LRS kit, used in conjunction with other instrumentation in our laboratory, allowed researchers to identify potential biomarkers of breast and colon cancer. NYU states that this is significant finding, as the potential biomarkers may prove to be important indicators of disease detection and progression.

Dr. Pevsner also stated that “the combination of PCT and ProteoSolve-LRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well."

*The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the Company mentioned in this report. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company with in the last three years. In October, 2006, the company paid a monetary engagement fee of $19,500 (USD) for the first year of creation and dissemination of research reports and will pay a monthly monetary fee of $1,750 (USD) to Taglich Brothers, Inc. for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

To send this page to a friend, just fill out the form below and press the "send it" button!